Superstring Capital Management
Latest statistics and disclosures from Superstring Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are CYTK, LEGN, TERN, BBIO, ETNB, and represent 43.55% of Superstring Capital Management's stock portfolio.
- Added to shares of these 10 stocks: LEGN (+$6.9M), TERN (+$6.5M), ZLAB, ACLX, ARWR, CRBP, KROS, BGNE, NAMS, NVCR.
- Started 21 new stock positions in ARWR, LEGN, ACLX, CRBP, EYPT, MRSN, CMPS, NVCR, KPTI, SYRS. ZLAB, TERN, ATYR, NAMS, TNGX, CATX, BMEA, KURA, SYRE, BGNE, ZURA.
- Reduced shares in these 10 stocks: IDYA (-$9.5M), SVRA (-$7.5M), DAWN (-$5.8M), ROIV (-$5.6M), IONS (-$5.2M), CYTK, URGN, VRNA, BBIO, AVTE.
- Sold out of its positions in AVTE, Alpine Immune Sciences, ANNX, ASND, AUPH, RNA, AXSM, DAWN, DYN, IDYA. INZY, IONS, KALV, LYRA, PRAX, SY, VRNA, ROIV, URGN.
- Superstring Capital Management was a net seller of stock by $-38M.
- Superstring Capital Management has $79M in assets under management (AUM), dropping by -47.55%.
- Central Index Key (CIK): 0001931118
Tip: Access up to 7 years of quarterly data
Positions held by Superstring Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Superstring Capital Management
Superstring Capital Management holds 39 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Cytokinetics Com New (CYTK) | 12.8 | $10M | -32% | 188k | 54.18 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 8.6 | $6.9M | NEW | 155k | 44.29 |
|
| Terns Pharmaceuticals (TERN) | 8.2 | $6.5M | NEW | 957k | 6.81 |
|
| Bridgebio Pharma (BBIO) | 7.0 | $5.6M | -37% | 220k | 25.33 |
|
| 89bio (ETNB) | 6.9 | $5.5M | -27% | 680k | 8.01 |
|
| Nkarta (NKTX) | 6.5 | $5.2M | -26% | 876k | 5.91 |
|
| Zai Lab Adr (ZLAB) | 4.7 | $3.7M | NEW | 215k | 17.33 |
|
| Keros Therapeutics (KROS) | 4.3 | $3.4M | +119% | 74k | 45.70 |
|
| Arcellx Common Stock (ACLX) | 4.1 | $3.3M | NEW | 59k | 55.19 |
|
| Arrowhead Pharmaceuticals (ARWR) | 3.6 | $2.9M | NEW | 111k | 25.99 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 3.2 | $2.6M | NEW | 57k | 45.25 |
|
| Beigene Sponsored Adr (BGNE) | 2.2 | $1.8M | NEW | 13k | 142.67 |
|
| Fate Therapeutics (FATE) | 2.1 | $1.6M | -45% | 497k | 3.28 |
|
| Allogene Therapeutics (ALLO) | 2.0 | $1.6M | +32% | 690k | 2.33 |
|
| Pyxis Oncology Common Stock (PYXS) | 2.0 | $1.6M | 484k | 3.31 |
|
|
| Apogee Therapeutics (APGE) | 1.8 | $1.5M | -17% | 37k | 39.35 |
|
| Cytomx Therapeutics (CTMX) | 1.8 | $1.4M | +69% | 1.2M | 1.22 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 1.6 | $1.2M | NEW | 64k | 19.21 |
|
| Tourmaline Bio (TRML) | 1.5 | $1.2M | +36% | 95k | 12.86 |
|
| Novocure Ord Shs (NVCR) | 1.4 | $1.1M | NEW | 67k | 17.13 |
|
| Spyre Therapeutics Com New (SYRE) | 1.4 | $1.1M | NEW | 46k | 23.51 |
|
| Cabaletta Bio (CABA) | 1.3 | $1.0M | -51% | 140k | 7.48 |
|
| Tango Therapeutics (TNGX) | 1.2 | $992k | NEW | 116k | 8.58 |
|
| Allakos (ALLK) | 1.2 | $941k | -23% | 941k | 1.00 |
|
| Perspective Therapeutics Com New (CATX) | 1.1 | $874k | NEW | 88k | 9.97 |
|
| Savara (SVRA) | 1.0 | $806k | -90% | 200k | 4.03 |
|
| Biomea Fusion (BMEA) | 0.9 | $752k | NEW | 167k | 4.50 |
|
| Kura Oncology (KURA) | 0.9 | $746k | NEW | 36k | 20.59 |
|
| Zura Bio Class A Ord Shs (ZURA) | 0.7 | $548k | NEW | 157k | 3.50 |
|
| Atyr Pharma Com New (ATYR) | 0.6 | $488k | NEW | 313k | 1.56 |
|
| Pepgen (PEPG) | 0.6 | $467k | -74% | 29k | 15.96 |
|
| Karyopharm Therapeutics (KPTI) | 0.6 | $464k | NEW | 535k | 0.87 |
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 0.4 | $329k | NEW | 38k | 8.70 |
|
| Marinus Pharmaceuticals Com New (MRNS) | 0.4 | $306k | -53% | 262k | 1.17 |
|
| Mersana Therapeutics (MRSN) | 0.3 | $221k | NEW | 110k | 2.01 |
|
| Lakeshore Biopharma Ordinary Shares (LSB) | 0.3 | $200k | 308k | 0.65 |
|
|
| Compass Pathways Sponsored Ads (CMPS) | 0.2 | $196k | NEW | 33k | 6.04 |
|
| Syros Pharmaceuticals Com New (SYRS) | 0.2 | $195k | NEW | 38k | 5.16 |
|
| Spruce Biosciences (SPRB) | 0.1 | $40k | -82% | 78k | 0.52 |
|
Past Filings by Superstring Capital Management
SEC 13F filings are viewable for Superstring Capital Management going back to 2023
- Superstring Capital Management 2024 Q2 filed Aug. 14, 2024
- Superstring Capital Management 2024 Q1 filed May 15, 2024
- Superstring Capital Management 2023 Q4 filed Feb. 14, 2024